酰胺质子转移成像肝脏MRI:对局灶性肝脏病变定性的可行性与准确性
本研究纳入203例疑似局灶性肝脏病变患者,在3T下行单层快速自旋回波APT成像,技术成功率为62.1%(126/203)。在59个可分析病变中,肝转移瘤的MTRasym值显著高于肝细胞癌(0.13±2.15% vs. -1.41±3.68%,p=0.027)。作者认为APT成像可能成为鉴别局灶性肝脏病变的影像生物标志物,但临床应用前需进一步技术改进。
要点
- 肝脏APT成像技术成功率较低(62.1%),主要失败原因为B0不均匀和呼吸运动。
- 肝转移瘤的MTRasym值显著高于肝细胞癌(p=0.027)。
- APT成像有望作为鉴别局灶性肝脏病变的影像生物标志物,但需进一步技术改进。
核心结论
- APT成像可能成为鉴别局灶性肝脏病变的影像生物标志物,但临床应用前需进一步技术改进。
研究设计与样本
- 单中心可行性研究,纳入203例疑似局灶性肝脏病变患者,在3T行单层快速自旋回波APT成像,通过五次屏气采集,采集时间约1分钟,以3.5 ppm处的磁化传递率不对称(MTRasym)测量APT信号。
关键影像表现/征象
- 肝转移瘤的MTRasym值为0.13±2.15%,肝细胞癌的MTRasym值为-1.41±3.68%,肝转移瘤显著高于肝细胞癌(p=0.027)。
诊断标准与关键数值
- APT成像技术成功率为62.1%(126/203),失败原因包括B0不均匀(n=43)、显著呼吸运动(n=12)及两者兼有(n=22)。
- 在59个可分析APT图像的局灶性肝脏病变中,比较了27例肝转移瘤患者与23例肝细胞癌患者的MTRasym值。
局限性
- APT成像技术成功率相对较低(62.1%)。
- 需进一步技术改进后APT成像才能临床应用于肝脏MRI。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the feasibility of using amide proton transfer (APT) magnetic resonance imaging (MRI) in the liver and to evaluate its ability to characterize focal liver lesions (FLLs).
METHODS: A total of 203 patients with suspected FLLs who underwent APT imaging at 3T were included. APT imaging was obtained using a single-slice turbo spin-echo sequence to include FLLs through five breath-holds, and its acquisition time was approximately 1 min. APT signals in the background liver and FLL were measured with magnetization transfer ratio asymmetry (MTRasym) at 3.5 ppm. The technical success rate of APT imaging and the reasons for failure to obtain meaningful MTRasym values were assessed. The Mann Whitney U test was used to compare MTRasym values between different FLLs.
RESULTS: The technical success rate of APT imaging in the liver was 62.1% (126/203). The reasons for failure were a too large B0 inhomogeneity (n = 43), significant respiratory motion (n = 12), and these two factors together (n = 22), respectively. Among 59 FLLs with analyzable APT images, MTRasym values were compared between 27 patients with liver metastases and 23 patients with hepatocellular carcinomas (HCCs). The MTRasym values of metastases were significantly higher than those of HCC (0.13 ± 2.15% vs. - 1.41 ± 3.68%, p = 0.027).
CONCLUSIONS: APT imaging could be an imaging biomarker for the differentiation of FLLs. However, further technical improvement is required before APT imaging can be clinically applied to liver MRI.
KEY POINTS: • Liver APT imaging was technically feasible, but with a relatively low success rate (62.1%). • Liver metastases showed higher APT values than hepatocellular carcinomas.
引用
- Seo N, Jeong HK, Choi JY, et al. Liver MRI with amide proton transfer imaging: feasibility and accuracy for the characterization of focal liver lesions. Eur Radiol. 2020. PMID: 32785767. doi:10.1007/s00330-020-07122-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。